Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SCD | O00767 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL936283 | 0.91 | PANK3 (0.41) | PANK3SMN1; SMN2LMNAALPLCNR1 | |
| SCHEMBL20460443 | 0.84 | HPGD (0.49) | SMN1; SMN2LMNAALPLNPC1RAB9A | |
| SCHEMBL938256 | 0.83 | JUN (0.42) | PANK3LMNASCD | |
| SCHEMBL8310937 | 0.83 | NPC1 (0.47) | SMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL8310344 | 0.82 | JUN (0.48) | SMN1; SMN2ALPLCNR1 | |
| SCHEMBL12017919 | 0.82 | CNR1 (0.46) | PANK3SMN1; SMN2LMNACNR1NAMPT | |
| SCHEMBL936146 | 0.80 | JUN (0.47) | LMNASCD | |
| SCHEMBL8308548 | 0.80 | HPGD (0.54) | LMNAALPLRAB9A | |
| SCHEMBL20152022 | 0.79 | JUN (0.48) | LMNACNR1 | |
| SCHEMBL937430 | 0.79 | NAAA (0.50) | CNR1SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550073-B2 | Benzamide derivative | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2020-02-04 | — | — | US | disclosed |
| EP-3357916-A1 | BENZAMIDE DERIVATIVE | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2018-08-08 | — | — | EP | disclosed |
| EP-1648874-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-10-05 | — | — | EP | disclosed |
| US-7964591-B2 | Pyridazine derivatives and their use as therapeutic agents | NOVARTIS PHARMA AG (CH) | 2011-06-21 | — | — | US | disclosed |
| US-7951805-B2 | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase | XENON PHARMACEUTICALS INC. (CA) | 2011-05-31 | — | — | US | disclosed |
| EP-2316827-A1 | Piperazine derivatives and their use as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2011-05-04 | — | — | EP | disclosed |
| US-20110021530-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS IN THE TREATMENT OF SKIN DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2011-01-27 | — | — | US | disclosed |
| US-7799787-B2 | Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase | MERCK FROSST CANADA LTD. (CA) | 2010-09-21 | — | — | US | disclosed |
| US-20090088431-A1 | Heteroaromatic Compounds as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase | MERCK FROSST CANADA LTD. | 2009-04-02 | — | — | US | disclosed |
| WO-2009037542-A2 | SPIROCYCLIC COMPOUNDS AS STEAROYL COA DESATURASE INHIBITORS | GLENMARK PHARMACEUTICALS, S.A. (US) | 2009-03-26 | — | — | WO | disclosed |
| EP-1966183-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Ltd. (CA) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071023-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021530-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS IN THE TREATMENT OF SKIN DISORDERS | PRXL2A, CUTA, MC1R | PANK3 2671/4885SMN1; SMN2 746/4885LMNA 176/4885 |
| US-10550073-B2 | Benzamide derivative | CYP3A5, ABCB1, CYP2D6 | PANK3 3167/4885SMN1; SMN2 2610/4885LMNA 1300/4885 |
| US-20090088431-A1 | Heteroaromatic Compounds as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase | SCD, SCD5, SREBF1 | PANK3 2357/4885SMN1; SMN2 3057/4885LMNA 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.